Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534)

Chintagumpala MM, Perlman EJ, Tornwall B, Chi YY, Kim Y, Hoffer FA, Kalapurakal JA, Warwick AB, Shamberger RC, Khanna G, Hamilton TE, Gow KW, Paulino AC, Gratias EJ, Mullen EA, Geller JI, Fernandez CV, Ritchey ML, Grundy PE, Dome JS, Ehrlich PF. Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). Cancer. 2022 Jul 1;128(13):2493-2503. doi: 10.1002/cncr.34219. Epub 2022 Apr 5. PubMed PMID: 35383900; PubMed Central PMCID: PMC9177742.

An objective of AREN0534 was to improve survival for bilateral Wilms tumor (BWT) patients using preoperative chemotherapy of limited duration and tailoring postoperative therapy based on histopathologic response. We report outcomes based on postoperative histopathologic response. BWT patients were treated with vincristine (V), dactinomycin (A), and doxorubicin (D) for 6 or 12 weeks followed by surgery. Postoperative therapy was prescribed based on the highest risk tumor according to SIOP classification and the Children’s Oncology Group (COG) staging system.